VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its first quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, May 7, 2026.

Company Presentation Details:

A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change.

About Xenon Pharmaceuticals Inc. 

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective K_V7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K_V7 and Na_V1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X. 

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner. 

Contacts: 

For Investors:  
Tucker Kelly  
Chief Financial Officer  
investors@xenon-pharma.com  

For Media:  
Colleen Alabiso  
Senior Vice President, Corporate Affairs  
media@xenon-pharma.com